20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Up 74.8% in April

20/20 Biolabs Inc (NASDAQ:AIDX) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 33,116 shares, an increase of 74.8% from the April 15th total of 18,940 shares. Based on an average daily trading volume, of 61,031 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the stock are short sold.

20/20 Biolabs Stock Up 3.7%

Shares of AIDX traded up $0.05 during mid-day trading on Monday, reaching $1.39. The company had a trading volume of 61,890 shares, compared to its average volume of 233,733. The company’s fifty day simple moving average is $1.87. 20/20 Biolabs has a fifty-two week low of $1.26 and a fifty-two week high of $50.00.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.26) earnings per share for the quarter. The business had revenue of $0.54 million for the quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AIDX. Maxim Group began coverage on shares of 20/20 Biolabs in a research note on Monday, May 11th. They set a “buy” rating and a $5.00 price objective for the company. Weiss Ratings began coverage on shares of 20/20 Biolabs in a research note on Thursday. They set a “sell (e-)” rating for the company. Finally, Wall Street Zen raised shares of 20/20 Biolabs to a “hold” rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, 20/20 Biolabs has a consensus rating of “Hold” and a consensus target price of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.